Hyperammonemia Treatment MarketThe global hyperammonemia treatment market size is expected to reach a valuation of USD ...

Company of China, Ltd. (hereafter "Ping An", or the "Group", HKEX: 2318 / 82318; SSE: 601318) today announced its results for the nine months ended , 2024.  In the first nine months of 2024, China's ...

Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management and business ...

Up to half of patients showed significant improvement in study results presented at the American Academy of Ophthalmology ...

The agent is currently being evaluated in a phase 1a study, and a phase 1b/2a study will continue to assess LP-184’s safety ...

Theranexus has developed the first oral solution of miglustat tailored to the needs of patients with Niemann-Pick type C disease, Theranexus is preparing to register this formulation with the EMA ...

The FDA granted galinpepimut-S a rare pediatric disease designation for the treatment of pediatric patients with acute ...

The FDA grants rare pediatric disease designation for serious or life-threatening diseases that affect fewer than 200,000 people in the United States when those people are primarily younger than 18 ...

Theriva Biologics (NYSE American: TOVX), ("Theriva” or the "Company”), a clinical-stage company developing therapeutics ...

SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company, Tuesday announced that the U.S. Food and ...

GPS Currently Investigated in Phase 3 REGAL Trial in Adult AML Patients – Interim Analysis Anticipated in Q4 2024 - ...

Poster presentations include data supporting QTORIN™ rapamycin 3.9% anhydrous gel as a potential targeted therapy for the ...